S&P 500   3,931.85 (+0.39%)
DOW   32,178.07 (+0.99%)
QQQ   303.78 (-0.52%)
AAPL   155.05 (+0.03%)
MSFT   274.68 (-1.70%)
META   197.79 (+1.11%)
GOOGL   100.66 (-0.94%)
AMZN   97.25 (-1.72%)
TSLA   177.47 (-1.48%)
NVDA   257.70 (+0.17%)
NIO   8.11 (-1.82%)
BABA   79.88 (-2.19%)
AMD   96.24 (-1.64%)
T   18.30 (+0.94%)
F   11.29 (-0.09%)
MU   56.73 (+0.12%)
CGC   1.97 (-1.50%)
GE   90.90 (+0.68%)
DIS   93.75 (+0.59%)
AMC   4.21 (+0.72%)
PFE   40.12 (+0.05%)
PYPL   72.88 (-0.15%)
NFLX   297.05 (-2.13%)
S&P 500   3,931.85 (+0.39%)
DOW   32,178.07 (+0.99%)
QQQ   303.78 (-0.52%)
AAPL   155.05 (+0.03%)
MSFT   274.68 (-1.70%)
META   197.79 (+1.11%)
GOOGL   100.66 (-0.94%)
AMZN   97.25 (-1.72%)
TSLA   177.47 (-1.48%)
NVDA   257.70 (+0.17%)
NIO   8.11 (-1.82%)
BABA   79.88 (-2.19%)
AMD   96.24 (-1.64%)
T   18.30 (+0.94%)
F   11.29 (-0.09%)
MU   56.73 (+0.12%)
CGC   1.97 (-1.50%)
GE   90.90 (+0.68%)
DIS   93.75 (+0.59%)
AMC   4.21 (+0.72%)
PFE   40.12 (+0.05%)
PYPL   72.88 (-0.15%)
NFLX   297.05 (-2.13%)
S&P 500   3,931.85 (+0.39%)
DOW   32,178.07 (+0.99%)
QQQ   303.78 (-0.52%)
AAPL   155.05 (+0.03%)
MSFT   274.68 (-1.70%)
META   197.79 (+1.11%)
GOOGL   100.66 (-0.94%)
AMZN   97.25 (-1.72%)
TSLA   177.47 (-1.48%)
NVDA   257.70 (+0.17%)
NIO   8.11 (-1.82%)
BABA   79.88 (-2.19%)
AMD   96.24 (-1.64%)
T   18.30 (+0.94%)
F   11.29 (-0.09%)
MU   56.73 (+0.12%)
CGC   1.97 (-1.50%)
GE   90.90 (+0.68%)
DIS   93.75 (+0.59%)
AMC   4.21 (+0.72%)
PFE   40.12 (+0.05%)
PYPL   72.88 (-0.15%)
NFLX   297.05 (-2.13%)
S&P 500   3,931.85 (+0.39%)
DOW   32,178.07 (+0.99%)
QQQ   303.78 (-0.52%)
AAPL   155.05 (+0.03%)
MSFT   274.68 (-1.70%)
META   197.79 (+1.11%)
GOOGL   100.66 (-0.94%)
AMZN   97.25 (-1.72%)
TSLA   177.47 (-1.48%)
NVDA   257.70 (+0.17%)
NIO   8.11 (-1.82%)
BABA   79.88 (-2.19%)
AMD   96.24 (-1.64%)
T   18.30 (+0.94%)
F   11.29 (-0.09%)
MU   56.73 (+0.12%)
CGC   1.97 (-1.50%)
GE   90.90 (+0.68%)
DIS   93.75 (+0.59%)
AMC   4.21 (+0.72%)
PFE   40.12 (+0.05%)
PYPL   72.88 (-0.15%)
NFLX   297.05 (-2.13%)
NASDAQ:ACRX

AcelRx Pharmaceuticals - ACRX Stock Forecast, Price & News

$0.63
-0.03 (-4.55%)
(As of 03/20/2023 09:40 AM ET)
Add
Compare
Today's Range
$0.61
$0.67
50-Day Range
$0.66
$2.59
52-Week Range
$0.61
$7.60
Volume
42,712 shs
Average Volume
211,060 shs
Market Capitalization
$4.69 million
P/E Ratio
0.10
Dividend Yield
N/A
Price Target
N/A

AcelRx Pharmaceuticals MarketRank™ Forecast

Analyst Rating
N/A
Upside/​Downside
N/A
Short Interest
Bearish
8.30% of Float Sold Short
Dividend Strength
N/A
Sustainability
-2.41
Upright™ Environmental Score
News Sentiment
0.47mentions of AcelRx Pharmaceuticals in the last 14 days
Based on 6 Articles This Week
Insider Trading
N/A
Proj. Earnings Growth
N/A

Overall MarketRank

MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.

1.49 out of 5 stars


ACRX stock logo

About AcelRx Pharmaceuticals (NASDAQ:ACRX) Stock

AcelRx Pharmaceuticals, Inc. engages in the development and commercialization of therapies use in medically supervised settings. The firm's portfolio includes DSUVIA, DZUVEO, Zalviso, ARX-02 and ARX-03. The company was founded by Thomas A. Schreck and Pamela Pierce Palmer on July 13, 2005 and is headquartered in Hayward, CA.

Receive ACRX Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for AcelRx Pharmaceuticals and its competitors with MarketBeat's FREE daily newsletter.

ACRX Stock News Headlines

The "King Of Quants" sees 10X potential...
Eric Fry believes he just discovered America's next "Wealth Supercluster" and it's forming in the place you'd least expect. Investors are already flocking there for a chance at 1,000%+ returns. Here's how you could join them before it's too late...
Acelrx Pharmaceuticals
BREAKING: Tiny biotech successfully treats blindness
There's a tiny biotech in Cambridge that's using a breakthrough technology to treat blindness. This company has already shown success in human trials... And Our research shows that anyone who gets in today could see a 46,751% return.
AcelRx Pharmaceuticals Announces Reverse Stock Split
ACRX AcelRx Pharmaceuticals, Inc.
See More Headlines
Receive ACRX Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for AcelRx Pharmaceuticals and its competitors with MarketBeat's FREE daily newsletter.

ACRX Company Calendar

Last Earnings
11/15/2021
Today
3/20/2023
Next Earnings (Estimated)
3/23/2023
Fiscal Year End
12/31/2023

Industry, Sector and Symbol

Industry
Pharmaceutical preparations
Sub-Industry
N/A
Sector
Medical
Current Symbol
NASDAQ:ACRX
Employees
43
Year Founded
N/A

Profitability

Net Income
$-35,100,000.00
Net Margins
3,111.24%
Pretax Margin
3,112.16%

Debt

Sales & Book Value

Annual Sales
$2.82 million
Book Value
($6.02) per share

Miscellaneous

Free Float
7,032,000
Market Cap
$4.92 million
Optionable
Optionable
Beta
0.27

Key Executives

  • Vincent J. Angotti
    President, Chief Executive Officer & Director
  • Raffi Asadorian
    Chief Financial & Accounting Officer
  • Pamela Pierce Palmer
    Director & Chief Medical Officer
  • Badri N. Dasu
    Chief Engineering Officer
  • Mark A. Evashenk
    Vice President-Clinical Operations













ACRX Stock - Frequently Asked Questions

How have ACRX shares performed in 2023?

AcelRx Pharmaceuticals' stock was trading at $2.26 at the beginning of 2023. Since then, ACRX stock has decreased by 70.8% and is now trading at $0.66.
View the best growth stocks for 2023 here
.

Are investors shorting AcelRx Pharmaceuticals?

AcelRx Pharmaceuticals saw a increase in short interest in the month of February. As of February 28th, there was short interest totaling 666,600 shares, an increase of 7.9% from the February 13th total of 617,600 shares. Based on an average daily volume of 156,700 shares, the days-to-cover ratio is currently 4.3 days. Approximately 8.3% of the shares of the company are short sold.
View AcelRx Pharmaceuticals' Short Interest
.

When is AcelRx Pharmaceuticals' next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Thursday, March 23rd 2023.
View our ACRX earnings forecast
.

How were AcelRx Pharmaceuticals' earnings last quarter?

AcelRx Pharmaceuticals, Inc. (NASDAQ:ACRX) posted its quarterly earnings results on Monday, November, 15th. The specialty pharmaceutical company reported ($1.40) EPS for the quarter, meeting analysts' consensus estimates of ($1.40). The specialty pharmaceutical company had revenue of $1.86 million for the quarter, compared to the consensus estimate of $1.20 million. During the same period in the prior year, the business posted ($2.00) earnings per share.

When did AcelRx Pharmaceuticals' stock split?

AcelRx Pharmaceuticals's stock reverse split on the morning of Wednesday, October 26th 2022. The 1-20 reverse split was announced on Wednesday, October 26th 2022. The number of shares owned by shareholders was adjusted after the market closes on Wednesday, October 26th 2022. An investor that had 100 shares of stock prior to the reverse split would have 5 shares after the split.

What other stocks do shareholders of AcelRx Pharmaceuticals own?

Based on aggregate information from My MarketBeat watchlists, some companies that other AcelRx Pharmaceuticals investors own include Advanced Micro Devices (AMD), Novavax (NVAX), Amarin (AMRN), Amicus Therapeutics (fold), Inovio Pharmaceuticals (INO), TG Therapeutics (TGTX), OPKO Health (OPK), CyberArk Software (CYBR), Flexion Therapeutics (FLXN) and NVIDIA (NVDA).

What is AcelRx Pharmaceuticals' stock symbol?

AcelRx Pharmaceuticals trades on the NASDAQ under the ticker symbol "ACRX."

Who are AcelRx Pharmaceuticals' major shareholders?

AcelRx Pharmaceuticals' stock is owned by a number of retail and institutional investors. Top institutional shareholders include Armistice Capital LLC (4.93%), Tang Capital Management LLC (2.62%), Susquehanna International Group LLP (0.85%), Geode Capital Management LLC (0.81%), Values First Advisors Inc. (0.50%) and Texas Capital Bank Wealth Management Services Inc. (0.29%). Insiders that own company stock include Adrian Adams and Vincent J Angotti.
View institutional ownership trends
.

How do I buy shares of AcelRx Pharmaceuticals?

Shares of ACRX stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is AcelRx Pharmaceuticals' stock price today?

One share of ACRX stock can currently be purchased for approximately $0.66.

How much money does AcelRx Pharmaceuticals make?

AcelRx Pharmaceuticals (NASDAQ:ACRX) has a market capitalization of $4.92 million and generates $2.82 million in revenue each year. The specialty pharmaceutical company earns $-35,100,000.00 in net income (profit) each year or $6.26 on an earnings per share basis.

How can I contact AcelRx Pharmaceuticals?

AcelRx Pharmaceuticals' mailing address is 351 GALVESTON DRIVE, REDWOOD CITY CA, 94063. The official website for the company is www.acelrx.com. The specialty pharmaceutical company can be reached via phone at (650) 216-3500, via email at bkorb@troutgroup.com, or via fax at 650-216-6500.

This page (NASDAQ:ACRX) was last updated on 3/20/2023 by MarketBeat.com Staff